Reston, VA-The U.S. Food and Drug Administration (FDA) has granted full approval to Leqembi (lecanemab), which has been shown to slow the progression of Alzheimer's in patients with mild cognitive impairment or mild dementia; however, the Centers for Medicare & Medicaid Services (CMS) has not committed to reimbursement of the needed PET scans. Alzheimer's disease affects more than six million Americans and ranks as the sixth leading cause of death among U.S. adults. In 2022, the economic impact of Alzheimer's disease on the American economy was estimated at $321 billion.

https://www.miragenews.com/fda-approves-leqembi-for-alzheimers-cms-unclear-1044064/

#miragenews